Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

Slides:

Advertisements

Similar presentations

VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.

Advertisements

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

Why does PAT need Rapid Microbiology Methods? S.Lonardi, P.J.Newby, D.Ribeiro, B.Johnson PAT Subcommittee meeting October 23, 2002.

Current Statistical Issues in Dissolution Profile Comparisons

Lab 4: Most Probable Number Method (MPN)

FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.

R APID M ICRO M ETHODS PPAR 2013 Jeffrey W. Weber, PAT Project Manager Kalamazoo, MI Oct 2013.

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.

Pharmaceutical Nomenclature Issues and challenges Moheb M. Nasr, Ph.D. Acting Director Office of New Drug Chemistry (ONDC) OPS, CDER, FDA Advisory Committee.

Transition to Inspections: USP, 21 CFR 212, And Beyond? Panel Discussion Ravi S. Harapanhalli, Ph.D Louis Marzella, MD Ravindra Kasliwal, Ph.D Wendy Sanhai,

(c) 2002 Jeanne Moldenhauer1 Validation of Rapid Microbiology Systems Based upon PDA Technical Report No. 33.

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.

Technical Report on Alternative Methods for Mycoplasma Testing Status update- Sept 2008 Kurt Brorson, Ph.D. CDER/FDA.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

Chapter 1 Introduction to Course and HACCP. Objective In this module, you will learn the: u Objective of the course u Format of the course u Expectations.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

1 Bioequivalence of Highly Variable Drugs: Regulatory Perspectives Sam H. Haidar, R.Ph., Ph.D. Pharmacometrics Office of Generic Drugs.

Validating the Micro PRO™ Technology. Overview of Today’s Presentation Validation Resources Micro PRO™ Applications and Corresponding Validation Parameters.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

The Latest RBD 3000 Applications The Latest RBD 3000 Applications Advanced Analytical User’s Meeting November 30, 2006 Chicago, IL.

10/11/ ENGINEERING RESEARCH CENTER FOR S TRUCTURED O RGANIC P ARTICULATE S YSTEMS RUTGERS UNIVERSITY PURDUE UNIVERSITY NEW JERSEY INSTITUTE OF TECHNOLOGY.

Overview of FDA's Regulatory Framework for PET Drugs

Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Generic Industry’s Perspective on the New GMP Initiative May 21, 2003 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance.

1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

CTD Dossier Preparation K. Srikantha Reddy Sr

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

Lab 8: Most Probable Number Method (MPN). Most Probable Number Method (MPN) What is the MPN method? How to determine the amount of bacteria from the MPN.

Process Understanding and PAT

Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA

Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.

Laboratory Perspective on Testing Methodologies Wendy Warren-Serna, Ph.D. USDA-FSIS Public Meeting Control of E. coli O157:H7.

1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.

ICH Quality Topics Update

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

Microbial Limit Testing Technology Overview Advisory Committee for Pharmaceutical Science July 19, 2001.

Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.

USDA Public Meeting; Control of E. coli O157:H7

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

Rapid Microbiology Methods Industry Concerns Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc.

© G.K.Raju, Ph.D. Manufacturing Science May 21st 2003 MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century.. G.K.Raju, Ph.D.

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

Webinar On Transfer of Analytical Methods and Procedures according to USP 1224 Presented By Dr. Ludwig Huber Webinar On Transfer of Analytical Methods.

USP: Water for Pharmaceutical Purposes NCSLI – Metrological Traceability in Pure Water Testing August 22, 2011 Antonio Hernandez-Cardoso Senior Scientific.

Generic Industry’s Perspective on the New GMP Initiative 2002 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance TEVA.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Grade A Dairy Equivalence

Application of rapid methods for the risk assessment of pharmaceutical processes Tim Sandle, Ph.D.

Analytical Method Validation PAI Readiness / Certification

Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.

Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT

Presentation transcript:

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office of Pharmaceutical Science PDA Sterile Manufacturing Practices in the Third Millennium: A Regulatory and Industry Perspective Milan, Italy June 2003

Bryan S. Riley, Ph.D.2 FDA Experience Release Tests –Microbial Limits –Sterility Other –Water –Bioburden –Environmental Monitoring

June 2003Bryan S. Riley, Ph.D.3 Micro Methods Overview Traditional Methods (plate counts, mpn) –simple –inexpensive –accepted Rapid Methods –fast –sensitive

June 2003Bryan S. Riley, Ph.D.4 FDA Concerns Increased Sensitivity of Rapid Methods –changing (raising?) microbial limits acceptance criteria Sterility Test “False Positives” –clear criteria for invalidation of test result

June 2003Bryan S. Riley, Ph.D.5 Validation Test Organisms –Compendial Organisms –Environmental Isolates Sample Specific Issues –Inhibition/Interference –Parallel Testing

June 2003Bryan S. Riley, Ph.D.6 Validation Equivalent or Better? Guidance –PDA Technical Report 33 - Evaluation, Validation and Implementation of New Microbiological Testing Methods –USP Draft Chapter - Validation of Alternative Microbiological Methods

June 2003Bryan S. Riley, Ph.D.7 FDA Initiatives Process Analytical Technology (PAT) –Includes rapid micro Microbiology Subcommittee for ACPS GMP’s for the 21 st Century –Product specialists for inspections –Dispute resolution process at Center level

June 2003Bryan S. Riley, Ph.D.8 Summary Rapid Methods vs. Traditional Methods –Is there a comparison? Apprehension by Industry –Why?

June 2003Bryan S. Riley, Ph.D.9 What Next? Meet with CDER Microbiologists –Validation issues –Filing requirements Submit applications containing rapid microbiology methods